Tarrant McPherson

Tarrant McPherson

Auto-generated profile, based on publicly available information

Tarrant McPherson

Emory University Atlanta California USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2026 in Blood Red Cells & Iron
Verified
Journal Article
Open access
SWSean Woo
Sean Woo
KPKernyu Park
Kernyu Park
TMTarrant McPherson
Tarrant McPherson
JWJanghee Woo
Janghee Woo

4 August 2026 in Epilepsia
Verified
Journal Article
Closed access
PDF file
AVAlexandria Valdrighi
Alexandria Valdrighi
KPKevin Pearsson
Kevin Pearsson
JPJurriaan Peters
Jurriaan Peters
TMTarrant McPherson
Tarrant McPherson
YLYuchen Li
Yuchen Li
BPBrenda Elaine Porter
Brenda Elaine Porter

20 March 2026 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
ESEva Strijbis
Eva Strijbis
JMJop Mostert
Jop Mostert
MDMiguel D’haeseleer
Miguel D’haeseleer
EMEster Moral
Ester Moral
LRLuis Brieva Ruiz
Luis Brieva Ruiz
MKMarcus Koch
Marcus Koch
Background and Objectives: It remains uncertain whether the relative benefit of disease-modifying treatments (DMTs) diminish as patients age because of a natural decline of inflammatory disease activity. To better capture the balance of benefit and harm, the statistical concept of the Number Needed to Treat (NNT) provides a useful and easily interpretable metric. Methods: We examined the relationship between treatment efficacy and age by applying the NNT concept to three pivotal randomized clinical trials of high-efficacy DMTs: AFFIRM, SENTINEL, and DECIDE (3,954 participants together). NNTs were calculated to determine how many individuals within each age group would need to be treated to prevent one additional inflammatory event (by different definitions of significant inflammation). Results: Inflammatory disease activity decreased with advancing age, resulting in progressively higher NNTs in older participants. For instance, in the SENTINEL trial, the NNT to prevent one additional new/enlarging T2 lesion annually was one for the youngest patients (⩽30 years) compared with 10 for the oldest (>50 years). Similarly, in AFFIRM, the NNT to prevent one relapse was two in the youngest group (⩽30 years) versus four in the oldest (41–50 years). Discussion: NNTs provide a framework for contextualizing treatment efficacy against potential harms, supporting more individualized therapeutic decision-making.